-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

Benzinga·10/08/2026 14:57:12
Diffusion vocale
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.